A shot in the arm for Australian biotech

Cephalon Inc.'s acquisition of SIRTeX Medical Technologies Ltd. for $161 million in cash provides proof-of-concept that Australian biotech can create value that attracts the attention of the outside world. But given their geographic and temporal distance from the rest of the world, Australian companies need to build additional infrastructure to connect science with business on a global level. And, as in the rest of the

Read the full 653 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE